{
    "clinical_study": {
        "@rank": "8366", 
        "arm_group": [
            {
                "arm_group_label": "Bifidobacterium viable pharmaceutics", 
                "arm_group_type": "Experimental", 
                "description": "Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks"
            }, 
            {
                "arm_group_label": "Berberine Hydrochloride", 
                "arm_group_type": "Experimental", 
                "description": "Berberine Hydrochloride, 0.5g, 2/day, 12 weeks"
            }, 
            {
                "arm_group_label": "lifestyle counseling", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to assess the beneficial effects of Bifidobacterium Hydrochloride\n      and Berberine on lowering glucose in patients with type 2 diabetes mellitus and to detect\n      the potential mechanism."
        }, 
        "brief_title": "Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "Gut microbiota maybe play an important role in patients with type 2 diabetes mellitus\n      (T2DM). Berberine, which is usually used as an antibiotic drug, has been reported a\n      potential glucose-lowering effect in vitro and in vivo studies. Bifidobacterium, as a\n      familiar probiotics, can modulate gut microbiota and improve glucose and lipid metabolism in\n      animal experiments. Therefore, the aim of this study is to assess the beneficial effects of\n      Bifidobacterium Hydrochloride and Berberine on lowering glucose in patients with T2DM and to\n      detect the potential mechanism."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any trial-related activities\uff1b\n\n          -  Male or female between 18 and 70 years of age\n\n          -  19\u2264Body mass index(BMI)\u226430kg/m2\n\n          -  No participate in any clinical trial at least 3 months\n\n          -  Newly diagnosed T2DM (OGTT) or not received previous pharmacological treatment\n\n          -  7%\u2264HbA1c\u22649%\n\n          -  Females in child-bearing period should be given birth control\n\n          -  No severe disease about heart, lung and kidney\n\n          -  Ability and willingness to adhere to the protocol including performance of\n             self-monitored blood glucose (SMBG) profiles according to the protocol\n\n          -  Subject is likely to comply with the Investigators instruction\n\n        Exclusion Criteria:\n\n          -  Type 2 or 1 diabetes mellitus received previous pharmacological treatment\n\n          -  Females of childbearing potential who are pregnant\uff0cbreastfeeding or intend to become\n             pregnant or are not using adequate contraceptive methods\n\n          -  Impaired liver function, defined as  Aspartate aminotransferase\uff08AST\uff09 or Alanine\n             transaminase (ALT)> 2 times upper limit of normal (central laboratory)\n\n          -  Impaired renal function, defined as serum-creatinine\u2265133\u03bcmol/L\n\n          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure\u2265160mmHg\n             and /or diastolic blood pressure\u226595mmHg)\n\n          -  Chronic gastrointestinal diseases\n\n          -  Cancer and medical history of cancer (except basal cell skin cancer or squamous cell\n             skin cancer)\n\n          -  Any clinically significant disease or disorder, which in the Investigator's opinion\n             could interfere with the results of the trial\n\n          -  Mental incapacity, psychiatric disorder, unwillingness or language barriers\n             precluding adequate understanding or co-operation, including subjects not able to\n             read and write\n\n          -  Previous participation in this trial. Participation is defined as randomized.\n             Re-screening of screening failures is allowed only once within the limits of the\n             recruitment period\n\n          -  Known or suspected hypersensitivity to trial products or related products\n\n          -  Known or suspected abuse of alcohol, narcotics or illicit drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "310", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084004", 
            "org_study_id": "2013KTZB03-02-01A"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bifidobacterium viable pharmaceutics", 
                "intervention_name": "Bifidobacterium viable pharmaceutics", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Berberine Hydrochloride", 
                "intervention_name": "Berberine Hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 2 diabetes mellitus", 
            "Berberine Hydrochloride", 
            "Bifidobacterium"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "BingYin Shi, Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shaanxi", 
                        "zip": "710061"
                    }, 
                    "name": "First Affiliated Hospital of Xi'an Jiaotong University"
                }, 
                "investigator": {
                    "last_name": "BingYin Shi, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xuan Xie, Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shaanxi", 
                        "zip": "710004"
                    }, 
                    "name": "Second Affiliated Hospital of Xi'an Jiaotong University"
                }, 
                "investigator": {
                    "last_name": "Xuan Xie, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "YangWei Wang, Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shaanxi", 
                        "zip": "710068"
                    }, 
                    "name": "Shaanxi Provincial People's Hospital"
                }, 
                "investigator": {
                    "last_name": "YangWei Wang, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "PeiJun Mao, Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China", 
                        "state": "Shaanxi", 
                        "zip": "710054"
                    }, 
                    "name": "The 323rd Hospital of People's Liberation Army"
                }, 
                "investigator": {
                    "last_name": "PeiJun Mao, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment\uff1aan Open-label, Multicenter\uff0cRandomized, Prospective\uff0cControlled Study", 
        "overall_contact": {
            "email": "qiuheji@hotmail.com", 
            "last_name": "Qiuhe Ji, Ph.D.,M.D."
        }, 
        "overall_contact_backup": {
            "email": "mingjie1207@163.com", 
            "last_name": "Jie Ming, M.D."
        }, 
        "overall_official": {
            "affiliation": "Department of Endocrinology, Xijing Hospital, Fourth Military Medical University", 
            "last_name": "Qiuhe Ji, Ph.D.,M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change was measured at baseline and week 12 after randomization. Change was reported as the absolute difference in % HbA1c.", 
            "measure": "Change in HbA1c from baseline to week 12", 
            "safety_issue": "No", 
            "time_frame": "Baseline and week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084004"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of subjects achieving HbA1c < 7% at week 12", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Faecal bacterial composition determined from microbiological cultures and deep metagenomic next-generation sequencing of bacterial DNA in feces.", 
                "measure": "Gut microbiome composition", 
                "safety_issue": "No", 
                "time_frame": "Baseline and week 12"
            }, 
            {
                "description": "Plasma level of GLP-1 at baseline and week 12 during a 2 hour-meal test.", 
                "measure": "Changes in postprandial glucagon-like peptide-1 (GLP-1) secretion between baseline and week 12", 
                "safety_issue": "No", 
                "time_frame": "Baseline and week 12"
            }, 
            {
                "description": "Standardized questionaries regarding gastrointestinal function are filled out at each study visit (0, 4, 8 and 12 weeks after randomization) to detect possible adverse effects of antibiotics. In addition, subjects are given a calendar and informed to write down any symptom or illness during the study period.", 
                "measure": "Adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to week 12"
            }
        ], 
        "source": "Xijing Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xijing Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}